Psoriasis, biologic therapy, and the pandemic of the 21st century.
COVID-19
SARS-CoV-2
biologic
coronavirus
psoriasis
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
04
2020
revised:
30
04
2020
accepted:
01
05
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
2
6
2020
Statut:
epublish
Résumé
The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.
Identifiants
pubmed: 32477419
doi: 10.7573/dic.2020-4-10
pii: dic-2020-4-10
pmc: PMC7233295
pii:
doi:
Types de publication
Editorial
Langues
eng
Informations de copyright
Copyright © 2020 Nogueira M, Vender R, Torres T.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: Miguel Nogueira has no conflicts of interest. Ron Vender has participated in clinical trials and has received honoraria for acting as a consultant and/or as a speaker at events sponsored by AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Galderma, GSK, Janssen, LEO-Pharma, Eli-Lilly, MSD, Novartis, UCB, and Pfizer. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO-Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung Bioepis, Sanofi-Genzyme, and Sandoz. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-4-10-COI.pdf
Références
J Dermatolog Treat. 2020 May 5;:1-2
pubmed: 32323591
Dermatol Ther (Heidelb). 2020 Apr 16;:1-11
pubmed: 32300516
Am J Clin Dermatol. 2020 Apr 10;:
pubmed: 32277351
Drugs Context. 2019 Jul 09;8:212594
pubmed: 31391856
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Cell Biol. 2016;2016:9259646
pubmed: 28083070
Br J Dermatol. 2020 Apr 28;:
pubmed: 32343839
Aliment Pharmacol Ther. 2012 May;35(9):971-86
pubmed: 22443153
J Am Acad Dermatol. 2020 May;82(5):1217-1218
pubmed: 32199889
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
JAMA. 2020 Feb 24;:
pubmed: 32091533
J Eur Acad Dermatol Venereol. 2020 Apr 15;:
pubmed: 32294258
J Dermatolog Treat. 2020 Jun;31(4):317-318
pubmed: 32191143